Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on May 1, 2017. The report addresses the closing of an underwritten secondary public offering of Class A common stock previously disclosed on March 31, 2017.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the execution of a secondary stock offering by selling stockholders rather than the company's operational financial performance.
Material Changes
- Overallotment Exercise: Underwriters exercised in full their option to purchase an additional 1,125,000 shares of Class A common stock from the Selling Stockholders.
- Closing Date: The sale of these shares pursuant to the Overallotment Option closed on May 1, 2017.
- Transaction Scope: This transaction is part of a larger offering of 7,500,000 shares, with the underwriters represented by J.P. Morgan Securities LLC and Goldman, Sachs & Co.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to future operations. The primary event reported is the legal and procedural completion of the stock sale by affiliates of TPG Global, LLC, The Advisory Board Company, UPMC, and Ptolemy Capital, LLC.
Key Facts for Investor Verification
- Verify the total number of shares sold in the full offering (7,500,000 base shares plus 1,125,000 overallotment shares).
- Confirm that the proceeds from this transaction went to the Selling Stockholders, not to Evolent Health, Inc.
- Review the March 31, 2017 Form 8-K for the initial terms of the underwriting agreement.
- Note that the company is classified as an emerging growth company.